Logo image of IBAB.BR

ION BEAM APPLICATIONS (IBAB.BR) Stock Fundamental Analysis

Europe - Euronext Brussels - EBR:IBAB - BE0003766806 - Common Stock

12.9 EUR
+0.76 (+6.26%)
Last: 12/29/2025, 10:18:10 AM
Fundamental Rating

4

Taking everything into account, IBAB scores 4 out of 10 in our fundamental rating. IBAB was compared to 62 industry peers in the Health Care Equipment & Supplies industry. IBAB has a medium profitability rating, but doesn't score so well on its financial health evaluation. IBAB is not valued too expensively and it also shows a decent growth rate.


Dividend Valuation Growth Profitability Health

5

1. Profitability

1.1 Basic Checks

In the past year IBAB was profitable.
IBAB had a positive operating cash flow in the past year.
IBAB had positive earnings in 4 of the past 5 years.
In multiple years IBAB reported negative operating cash flow during the last 5 years.
IBAB.BR Yearly Net Income VS EBIT VS OCF VS FCFIBAB.BR Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 50M -50M 100M

1.2 Ratios

IBAB's Return On Assets of 2.71% is in line compared to the rest of the industry. IBAB outperforms 45.16% of its industry peers.
The Return On Equity of IBAB (14.29%) is better than 82.26% of its industry peers.
IBAB has a better Return On Invested Capital (15.54%) than 93.55% of its industry peers.
Measured over the past 3 years, the Average Return On Invested Capital for IBAB is below the industry average of 9.74%.
The 3 year average ROIC (6.20%) for IBAB is below the current ROIC(15.54%), indicating increased profibility in the last year.
Industry RankSector Rank
ROA 2.71%
ROE 14.29%
ROIC 15.54%
ROA(3y)0.32%
ROA(5y)1.58%
ROE(3y)1.66%
ROE(5y)6.12%
ROIC(3y)6.2%
ROIC(5y)6.71%
IBAB.BR Yearly ROA, ROE, ROICIBAB.BR Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 20 -20

1.3 Margins

The Profit Margin of IBAB (2.85%) is comparable to the rest of the industry.
IBAB's Profit Margin has declined in the last couple of years.
IBAB has a Operating Margin (6.48%) which is comparable to the rest of the industry.
IBAB's Operating Margin has improved in the last couple of years.
The Gross Margin of IBAB (31.21%) is worse than 82.26% of its industry peers.
In the last couple of years the Gross Margin of IBAB has remained more or less at the same level.
Industry RankSector Rank
OM 6.48%
PM (TTM) 2.85%
GM 31.21%
OM growth 3Y8.91%
OM growth 5Y47.94%
PM growth 3Y14.44%
PM growth 5Y-7.16%
GM growth 3Y-1.07%
GM growth 5Y0.22%
IBAB.BR Yearly Profit, Operating, Gross MarginsIBAB.BR Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 20 40

2

2. Health

2.1 Basic Checks

IBAB has a Return on Invested Capital (ROIC), which is well above the Cost of Capital (WACC), which means it is creating value.
The number of shares outstanding for IBAB has been increased compared to 1 year ago.
Compared to 5 years ago, IBAB has less shares outstanding
The debt/assets ratio for IBAB is higher compared to a year ago.
IBAB.BR Yearly Shares OutstandingIBAB.BR Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 5M 10M 15M 20M 25M
IBAB.BR Yearly Total Debt VS Total AssetsIBAB.BR Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 200M 400M 600M

2.2 Solvency

Based on the Altman-Z score of 1.65, we must say that IBAB is in the distress zone and has some risk of bankruptcy.
Looking at the Altman-Z score, with a value of 1.65, IBAB is doing worse than 66.13% of the companies in the same industry.
IBAB has a Debt/Equity ratio of 0.23. This is a healthy value indicating a solid balance between debt and equity.
With a decent Debt to Equity ratio value of 0.23, IBAB is doing good in the industry, outperforming 64.52% of the companies in the same industry.
Industry RankSector Rank
Debt/Equity 0.23
Debt/FCF N/A
Altman-Z 1.65
ROIC/WACC2.15
WACC7.23%
IBAB.BR Yearly LT Debt VS Equity VS FCFIBAB.BR Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 50M -50M 100M 150M

2.3 Liquidity

IBAB has a Current Ratio of 0.94. This is a bad value and indicates that IBAB is not financially healthy enough and could expect problems in meeting its short term obligations.
Looking at the Current ratio, with a value of 0.94, IBAB is doing worse than 85.48% of the companies in the same industry.
A Quick Ratio of 0.62 indicates that IBAB may have some problems paying its short term obligations.
IBAB has a worse Quick ratio (0.62) than 85.48% of its industry peers.
Industry RankSector Rank
Current Ratio 0.94
Quick Ratio 0.62
IBAB.BR Yearly Current Assets VS Current LiabilitesIBAB.BR Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 100M 200M 300M 400M 500M

6

3. Growth

3.1 Past

IBAB shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 112.86%, which is quite impressive.
IBAB shows a small growth in Earnings Per Share. Measured over the last years, the EPS has been growing by 3.99% yearly.
The Revenue has grown by 15.96% in the past year. This is quite good.
The Revenue has been growing by 12.01% on average over the past years. This is quite good.
EPS 1Y (TTM)112.86%
EPS 3Y33.53%
EPS 5Y3.99%
EPS Q2Q%75.35%
Revenue 1Y (TTM)15.96%
Revenue growth 3Y16.76%
Revenue growth 5Y12.01%
Sales Q2Q%47.7%

3.2 Future

Based on estimates for the next years, IBAB will show a very strong growth in Earnings Per Share. The EPS will grow by 58.72% on average per year.
IBAB is expected to show a small growth in Revenue. In the coming years, the Revenue will grow by 2.63% yearly.
EPS Next Y141.9%
EPS Next 2Y109.12%
EPS Next 3Y67.72%
EPS Next 5Y58.72%
Revenue Next Year23.68%
Revenue Next 2Y13.14%
Revenue Next 3Y10.36%
Revenue Next 5Y2.63%

3.3 Evolution

The EPS growth rate is accelerating: in the next years the growth will be better than in the last years.
When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is decreasing.
IBAB.BR Yearly Revenue VS EstimatesIBAB.BR Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 200M 400M 600M
IBAB.BR Yearly EPS VS EstimatesIBAB.BR Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 0 0.5 1 1.5

5

4. Valuation

4.1 Price/Earnings Ratio

A Price/Earnings ratio of 22.63 indicates a rather expensive valuation of IBAB.
Based on the Price/Earnings ratio, IBAB is valued a bit cheaper than the industry average as 79.03% of the companies are valued more expensively.
IBAB is valuated at similar levels of the S&P average when we compare the Price/Earnings ratio to 26.92, which is the current average of the S&P500 Index.
IBAB is valuated correctly with a Price/Forward Earnings ratio of 12.22.
IBAB's Price/Forward Earnings ratio is rather cheap when compared to the industry. IBAB is cheaper than 82.26% of the companies in the same industry.
When comparing the Price/Forward Earnings ratio of IBAB to the average of the S&P500 Index (23.46), we can say IBAB is valued slightly cheaper.
Industry RankSector Rank
PE 22.63
Fwd PE 12.22
IBAB.BR Price Earnings VS Forward Price EarningsIBAB.BR Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 5 10 15 20 25

4.2 Price Multiples

Based on the Enterprise Value to EBITDA ratio, IBAB is valued cheaper than 85.48% of the companies in the same industry.
Industry RankSector Rank
P/FCF N/A
EV/EBITDA 8.32
IBAB.BR Per share dataIBAB.BR EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 5 10 15

4.3 Compensation for Growth

IBAB's low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
A more expensive valuation may be justified as IBAB's earnings are expected to grow with 67.72% in the coming years.
PEG (NY)0.16
PEG (5Y)5.68
EPS Next 2Y109.12%
EPS Next 3Y67.72%

3

5. Dividend

5.1 Amount

With a Yearly Dividend Yield of 1.38%, IBAB has a reasonable but not impressive dividend return.
Compared to an average industry Dividend Yield of 1.11, IBAB pays a bit more dividend than its industry peers.
Compared to the average S&P500 Dividend Yield of 2.00, IBAB is paying slightly less dividend.
Industry RankSector Rank
Dividend Yield 1.38%

5.2 History

Dividend Growth(5Y)N/A
Div Incr Years0
Div Non Decr Years0
IBAB.BR Yearly Dividends per shareIBAB.BR Yearly Dividends per shareYearly Dividends per share 2020 2021 2022 2023 2024 2025 0.05 0.1 0.15 0.2

5.3 Sustainability

IBAB pays out 8.05% of its income as dividend. This is a sustainable payout ratio.
DP8.05%
EPS Next 2Y109.12%
EPS Next 3Y67.72%
IBAB.BR Yearly Income VS Free CF VS DividendIBAB.BR Yearly Income VS Free CF VS DividendYearly Income VS Free CF VS Dividend 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 50M -50M
IBAB.BR Dividend Payout.IBAB.BR Dividend Payout, showing the Payout Ratio.IBAB.BR Dividend Payout.PayoutRetained Earnings

ION BEAM APPLICATIONS

EBR:IBAB (12/29/2025, 10:18:10 AM)

12.9

+0.76 (+6.26%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Equipment & Supplies
Earnings (Last)11-20 2025-11-20
Earnings (Next)03-27 2026-03-27/amc
Inst Owners25.97%
Inst Owner ChangeN/A
Ins OwnersN/A
Ins Owner ChangeN/A
Market Cap390.61M
Revenue(TTM)596.63M
Net Income(TTM)17.00M
Analysts80
Price Target14.62 (13.33%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield 1.38%
Yearly Dividend0.17
Dividend Growth(5Y)N/A
DP8.05%
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)-2.27%
PT rev (3m)-2.27%
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)-13.91%
EPS NY rev (3m)-10.89%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)2.04%
Revenue NY rev (3m)1.99%
Valuation
Industry RankSector Rank
PE 22.63
Fwd PE 12.22
P/S 0.65
P/FCF N/A
P/OCF 140.31
P/B 3.28
P/tB 4.14
EV/EBITDA 8.32
EPS(TTM)0.57
EY4.42%
EPS(NY)1.06
Fwd EY8.18%
FCF(TTM)-0.18
FCFYN/A
OCF(TTM)0.09
OCFY0.71%
SpS19.7
BVpS3.93
TBVpS3.12
PEG (NY)0.16
PEG (5Y)5.68
Graham Number7.1
Profitability
Industry RankSector Rank
ROA 2.71%
ROE 14.29%
ROCE 25.19%
ROIC 15.54%
ROICexc 16.45%
ROICexgc 19.79%
OM 6.48%
PM (TTM) 2.85%
GM 31.21%
FCFM N/A
ROA(3y)0.32%
ROA(5y)1.58%
ROE(3y)1.66%
ROE(5y)6.12%
ROIC(3y)6.2%
ROIC(5y)6.71%
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)10.19%
ROCE(5y)10.93%
ROICexgc growth 3YN/A
ROICexgc growth 5Y52.5%
ROICexc growth 3Y-88.2%
ROICexc growth 5Y50.32%
OM growth 3Y8.91%
OM growth 5Y47.94%
PM growth 3Y14.44%
PM growth 5Y-7.16%
GM growth 3Y-1.07%
GM growth 5Y0.22%
F-Score7
Asset Turnover0.95
Health
Industry RankSector Rank
Debt/Equity 0.23
Debt/FCF N/A
Debt/EBITDA 0.54
Cap/Depr 65.94%
Cap/Sales 1.38%
Interest Coverage 250
Cash Conversion 5.44%
Profit Quality N/A
Current Ratio 0.94
Quick Ratio 0.62
Altman-Z 1.65
F-Score7
WACC7.23%
ROIC/WACC2.15
Cap/Depr(3y)79.57%
Cap/Depr(5y)64.6%
Cap/Sales(3y)2.05%
Cap/Sales(5y)1.81%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)112.86%
EPS 3Y33.53%
EPS 5Y3.99%
EPS Q2Q%75.35%
EPS Next Y141.9%
EPS Next 2Y109.12%
EPS Next 3Y67.72%
EPS Next 5Y58.72%
Revenue 1Y (TTM)15.96%
Revenue growth 3Y16.76%
Revenue growth 5Y12.01%
Sales Q2Q%47.7%
Revenue Next Year23.68%
Revenue Next 2Y13.14%
Revenue Next 3Y10.36%
Revenue Next 5Y2.63%
EBIT growth 1Y38.72%
EBIT growth 3Y27.16%
EBIT growth 5Y65.71%
EBIT Next Year221.54%
EBIT Next 3Y67.42%
EBIT Next 5Y52.9%
FCF growth 1Y90.8%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y105.87%
OCF growth 3YN/A
OCF growth 5YN/A

ION BEAM APPLICATIONS / IBAB.BR FAQ

Can you provide the ChartMill fundamental rating for ION BEAM APPLICATIONS?

ChartMill assigns a fundamental rating of 4 / 10 to IBAB.BR.


What is the valuation status for IBAB stock?

ChartMill assigns a valuation rating of 6 / 10 to ION BEAM APPLICATIONS (IBAB.BR). This can be considered as Fairly Valued.


How profitable is ION BEAM APPLICATIONS (IBAB.BR) stock?

ION BEAM APPLICATIONS (IBAB.BR) has a profitability rating of 5 / 10.


What is the valuation of ION BEAM APPLICATIONS based on its PE and PB ratios?

The Price/Earnings (PE) ratio for ION BEAM APPLICATIONS (IBAB.BR) is 22.63 and the Price/Book (PB) ratio is 3.28.


What is the earnings growth outlook for ION BEAM APPLICATIONS?

The Earnings per Share (EPS) of ION BEAM APPLICATIONS (IBAB.BR) is expected to grow by 141.9% in the next year.